-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Virtu Financial LLC Buys New Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)
Virtu Financial LLC Buys New Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)
Virtu Financial LLC bought a new stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 26,204 shares of the company's stock, valued at approximately $123,000. Virtu Financial LLC owned about 0.06% of Acumen Pharmaceuticals at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in the stock. New York State Common Retirement Fund boosted its holdings in shares of Acumen Pharmaceuticals by 337.5% during the 1st quarter. New York State Common Retirement Fund now owns 23,981 shares of the company's stock worth $94,000 after buying an additional 18,500 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Acumen Pharmaceuticals during the 1st quarter worth approximately $221,000. JPMorgan Chase & Co. boosted its holdings in shares of Acumen Pharmaceuticals by 149.3% during the 1st quarter. JPMorgan Chase & Co. now owns 18,049 shares of the company's stock worth $71,000 after buying an additional 10,809 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Acumen Pharmaceuticals by 259.6% during the 1st quarter. Bank of New York Mellon Corp now owns 68,971 shares of the company's stock worth $270,000 after buying an additional 49,791 shares in the last quarter. Finally, Rhumbline Advisers bought a new position in shares of Acumen Pharmaceuticals during the 1st quarter worth approximately $79,000. 63.33% of the stock is currently owned by institutional investors.
Get Acumen Pharmaceuticals alerts:Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on ABOS shares. BTIG Research increased their target price on Acumen Pharmaceuticals from $15.00 to $22.00 and gave the stock a "buy" rating in a report on Wednesday, October 5th. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Acumen Pharmaceuticals in a report on Tuesday, August 16th. Finally, Credit Suisse Group cut their target price on Acumen Pharmaceuticals from $17.00 to $16.00 and set an "outperform" rating on the stock in a report on Tuesday, November 15th.
Acumen Pharmaceuticals Price Performance
NASDAQ ABOS opened at $6.12 on Friday. The business has a fifty day simple moving average of $7.15 and a 200 day simple moving average of $5.78. Acumen Pharmaceuticals, Inc. has a 12 month low of $3.02 and a 12 month high of $10.97.Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) last released its quarterly earnings results on Monday, November 14th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. On average, analysts anticipate that Acumen Pharmaceuticals, Inc. will post -1.01 earnings per share for the current year.
Acumen Pharmaceuticals Company Profile
(Get Rating)
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Further Reading
- Get a free copy of the StockNews.com research report on Acumen Pharmaceuticals (ABOS)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Virtu Financial LLC bought a new stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 26,204 shares of the company's stock, valued at approximately $123,000. Virtu Financial LLC owned about 0.06% of Acumen Pharmaceuticals at the end of the most recent reporting period.
根據最近提交給美國證券交易委員會(納斯達克)的檔案,維圖金融有限責任公司在第二季度購買了Acumen製藥公司(美國證券交易委員會:ABOS-GET Rating)的新股份。該機構投資者購買了26,204股該公司股票,價值約12.3萬美元。在最近的報告期結束時,Virtu Financial LLC擁有Acumen製藥公司約0.06%的股份。
Several other institutional investors have also added to or reduced their stakes in the stock. New York State Common Retirement Fund boosted its holdings in shares of Acumen Pharmaceuticals by 337.5% during the 1st quarter. New York State Common Retirement Fund now owns 23,981 shares of the company's stock worth $94,000 after buying an additional 18,500 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Acumen Pharmaceuticals during the 1st quarter worth approximately $221,000. JPMorgan Chase & Co. boosted its holdings in shares of Acumen Pharmaceuticals by 149.3% during the 1st quarter. JPMorgan Chase & Co. now owns 18,049 shares of the company's stock worth $71,000 after buying an additional 10,809 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Acumen Pharmaceuticals by 259.6% during the 1st quarter. Bank of New York Mellon Corp now owns 68,971 shares of the company's stock worth $270,000 after buying an additional 49,791 shares in the last quarter. Finally, Rhumbline Advisers bought a new position in shares of Acumen Pharmaceuticals during the 1st quarter worth approximately $79,000. 63.33% of the stock is currently owned by institutional investors.
其他幾家機構投資者也增持或減持了該股。紐約州共同退休基金在第一季度增持了337.5%的Acumen PharmPharmticals股票。紐約州共同退休基金現在擁有23,981股該公司股票,價值94,000美元,上個季度又購買了18,500股。洛杉磯資本管理公司在第一季度購買了Acumen製藥公司的新股票頭寸,價值約221,000美元。摩根大通在第一季度增持了Acumen PharmPharmticals的股票,增幅為149.3%。摩根大通在上個季度又購買了10,809股,目前持有18,049股該公司股票,價值71,000美元。紐約梅隆銀行在第一季度增持了Acumen PharmPharmticals的股票,增幅為259.6%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有68,971股該公司股票,價值27萬美元,上一季度又購買了49,791股。最後,Rhumbline Advisers在第一季度購買了Acumen製藥公司的新頭寸,價值約7.9萬美元。63.33%的股票目前由機構投資者持有。
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of equities analysts recently issued reports on ABOS shares. BTIG Research increased their target price on Acumen Pharmaceuticals from $15.00 to $22.00 and gave the stock a "buy" rating in a report on Wednesday, October 5th. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Acumen Pharmaceuticals in a report on Tuesday, August 16th. Finally, Credit Suisse Group cut their target price on Acumen Pharmaceuticals from $17.00 to $16.00 and set an "outperform" rating on the stock in a report on Tuesday, November 15th.
多位股票分析師最近發佈了有關ABOS股票的報告。BTIG Research在10月5日(週三)的一份報告中將Acumen PharmPharmticals的目標價從15.00美元上調至22.00美元,並給予該股“買入”評級。在8月16日週二發佈的一份報告中,HC Wainwright重申了買入評級,並對Acumen PharmPharmticals的股票發佈了15.00美元的目標價。最後,瑞士信貸集團在11月15日週二的一份報告中將Acumen PharmPharmticals的目標價從17.00美元下調至16.00美元,並對該股設定了“跑贏大盤”的評級。
Acumen Pharmaceuticals Price Performance
Acumen製藥價格表現
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) last released its quarterly earnings results on Monday, November 14th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. On average, analysts anticipate that Acumen Pharmaceuticals, Inc. will post -1.01 earnings per share for the current year.
Acumen PharmPharmticals(納斯達克:ABOS-GET評級)最近一次發佈季度收益報告是在11月14日(星期一)。該公司公佈本季度每股收益(0.26美元),比分析師普遍預期的(0.27美元)高出0.01美元。分析師平均預計,Acumen PharmPharmticals,Inc.本年度每股收益為1.01美元。
Acumen Pharmaceuticals Company Profile
Acumen製藥公司簡介
(Get Rating)
(獲取評級)
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Acumen製藥公司是一家臨床階段的生物製藥公司,發現和開發治療阿爾茨海默病的療法。該公司專注於開發一種靶向免疫治療候選藥物ACU193,這是一種人源化單抗,正處於I期臨床階段,用於靶向可溶性澱粉樣β寡聚體。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Acumen Pharmaceuticals (ABOS)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- 免費獲取StockNews.com關於Acumen製藥的研究報告(ABOS)
- MarketBeat:回顧一週12/05-12/09
- 博通有基本面價值,收益率為3.35%
- 好市多VS亞馬遜:年底攤牌
- 折扣零售商可以做好的便宜貨
- 輝瑞、強生能否繼續跑贏該指數?
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Acumen PharmPharmticals Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Acumen製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧